We are live on
!
Find out more
VanEck Associates Portfolio holdings
AUM
$133B
1-Year Est. Return
72.99%
This Fund
S&P 500
This Quarter
Est. Return
+7.69%
1 Year Est. Return
+72.99%
3 Year Est. Return
+157.94%
5 Year Est. Return
+206.35%
10 Year Est. Return
+770.56%
AUM
$42.3B
AUM Growth
+$5.51B
(+15%)
Cap. Flow
+$3.13B
Cap. Flow
% of AUM
7.41%
Top 10 Holdings %
Top 10 Hldgs %
26.06%
Holding
1,338
New
111
Increased
793
Reduced
350
Closed
65
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SLB Ltd
SLB
|
+$238M |
| 2 |
CGAU
Centerra Gold
CGAU
|
+$212M |
| 3 |
Halliburton
HAL
|
+$181M |
| 4 |
Baker Hughes
BKR
|
+$115M |
| 5 |
ServiceNow
NOW
|
+$103M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gold Fields
GFI
|
+$374M |
| 2 |
John Wiley & Sons Class A
WLY
|
+$96.5M |
| 3 |
Bank of America
BAC
|
+$90.9M |
| 4 |
SCHW
Charles Schwab
SCHW
|
+$89.1M |
| 5 |
US Bancorp
USB
|
+$84.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Materials | 40.42% |
| 2 | Technology | 21.38% |
| 3 | Energy | 8.67% |
| 4 | Healthcare | 6.57% |
| 5 | Financials | 3.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
826
United Therapeutics
UTHR
$26.2B
| $841K | ﹤0.01% |
4,686
+467
| +11% | +$88.9K |
|
827
Chemed
CHE
$7.1B
| $835K | ﹤0.01% |
1,760
+198
| +13% | +$95.1K |
|
828
VanEck Short High Yield Muni ETF
SHYD
$451M
| $835K | ﹤0.01% |
32,796
-2,015
| -6% | -$50.8K |
|
829
BWX Technologies
BWXT
$15.2B
| $833K | ﹤0.01% |
14,329
+3,754
| +35% | +$241K |
|
|
NBH
830
Neuberger Municipal Fund Inc
NBH
$306M
| $832K | ﹤0.01% |
51,692
-822
| -2% | -$13.3K |
|
|
INFO
831
DELISTED
IHS Markit Ltd. Common Shares
INFO
| $826K | ﹤0.01% |
7,330
+1,642
| +29% | +$174K |
|
832
Huntington Ingalls Industries
HII
$12.6B
| $824K | ﹤0.01% |
3,909
+720
| +23% | +$153K |
|
833
Boston Beer
SAM
$1.93B
| $821K | ﹤0.01% |
804
+747
| +1,311% | +$838K |
|
|
ETX
834
Eaton Vance Municipal Income 2028 Term Trust
ETX
$198M
| $808K | ﹤0.01% |
34,717
+8,617
| +33% | +$194K |
|
835
Revvity
RVTY
$12.7B
| $805K | ﹤0.01% |
5,214
+207
| +4% | +$29.1K |
|
836
Nuveen Select Tax-Free Income Portfolio
NXP
$896M
| $804K | ﹤0.01% |
43,946
+3,181
| +8% | +$57K |
|
|
EQOS
837
DELISTED
EQONEX LIMITED Ordinary Shares
EQOS
| $804K | ﹤0.01% |
+122,860
| New | +$854K |
|
838
Labcorp
LH
$25.9B
| $800K | ﹤0.01% |
3,374
+227
| +7% | +$51.7K |
|
|
CXE
839
DELISTED
MFS High Income Municipal Trust
CXE
| $793K | ﹤0.01% |
150,129
+12,469
| +9% | +$66.3K |
|
|
SCHW
840
Charles Schwab
SCHW
$181B
| $791K | ﹤0.01% |
10,861
-1,259,113
| -99% | -$89.1M |
|
|
BNY
841
Bank of New York Mellon
BNY
$106B
| $784K | ﹤0.01% |
15,319
-1,567,924
| -99% | -$78.4M |
|
842
Canadian Natural Resources
CNQ
$98.6B
| $774K | ﹤0.01% |
43,564
+18,388
| +73% | +$303K |
|
|
NNDM
843
Nano Dimension
NNDM
$324M
| $773K | ﹤0.01% |
+93,760
| New | +$694K |
|
844
JFrog
FROG
$9.5B
| $772K | ﹤0.01% |
16,950
-6,292
| -27% | -$283K |
|
845
Sun Life Financial
SLF
$45.9B
| $767K | ﹤0.01% |
14,873
+1,866
| +14% | +$98.6K |
|
846
iShares MSCI United Kingdom ETF
EWU
$4.17B
| $757K | ﹤0.01% |
23,149
-5,579
| -19% | -$185K |
|
847
SEI Investments
SEIC
$12.4B
| $754K | ﹤0.01% |
12,166
+1,073
| +10% | +$66.9K |
|
848
Bio-Rad Laboratories Class A
BIO
$8.74B
| $753K | ﹤0.01% |
1,169
+47
| +4% | +$28.6K |
|
849
Universal Health Services
UHS
$9.88B
| $753K | ﹤0.01% |
5,144
+285
| +6% | +$43.1K |
|
850
Antero Midstream
AM
$10.2B
| $751K | ﹤0.01% |
72,313
-8,199
| -10% | -$78.3K |
|
Similar funds
VanEck Associates's Q2 2021 Portfolio in Review
As of Q2 2021, VanEck Associates held 1,338 positions worth $42.3B, up 15% from $36.8B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
VanEck Associates deployed $3.13B of net new capital in Q2 2021, opening 111 new positions and adding to 793 existing holdings. Its largest new stake was Centerra Gold: 25,491,475 shares worth $193M.
By sector, the portfolio is most concentrated in Materials at 40% of assets, down from 43% a quarter earlier, followed by Technology and Energy.
On the sell side, the largest reduction was Gold Fields, an estimated $374M trimmed.
- VanEck Associates's largest Q2 2021 buy was Centerra Gold: 25,491,475 shares worth $193M.
- VanEck Associates added most to SLB Ltd in Q2 2021, an estimated $238M increase.
- VanEck Associates's biggest Q2 2021 reduction was Gold Fields, cutting an estimated $374M.
- VanEck Associates fully exited John Wiley & Sons Class A in Q2 2021, selling an estimated $96.5M.
- VanEck Associates's ten largest holdings make up 26% of its $42.3B portfolio in Q2 2021.
- VanEck Associates opened 111 new positions and closed 65 in Q2 2021.
- VanEck Associates's portfolio value rose 15% quarter-over-quarter to $42.3B.
Based on VanEck Associates's 13F filing for Q2 2021, filed 10 Aug 2021.